Antibody-Mediated Rejection Infographics
Antibody-Mediated Rejection Market

Antibody-Mediated Rejection (AMR) or humoral rejection after renal transplantation is a devastating event that inevitably leads to allograft loss. Antibody-Mediated Rejection is caused by anti-donor-specific antibodies, especially anti-HLA antibodies.


Types of Antibody-Mediated Rejection:


  • Hyperacute Antibody-Mediated Rejection
  • Acute Antibody-Mediated Rejection
  • Chronic Antibody-Mediated Rejection


Antibody-Mediated Rejection Epidemiology Segmentation


  • Total prevalent cases of Antibody-Mediated Rejection 
  • Total diagnosed Antibody-Mediated Rejection prevalent cases 
  • Gender-specific diagnosed Antibody-Mediated Rejection prevalent cases
  • Age-specific diagnosed Antibody-Mediated Rejection prevalent cases
  • Gene-specific diagnosed Antibody-Mediated Rejection prevalent cases 


Antibody-Mediated Rejection Epidemiological Insights Observed in 2020


  • The total Antibody-Mediated Rejection incident cases in 7MM were observed to be 5,283.
  • The Antibody-Mediated Rejection incident population in the US was found to be 3,265 in 2020.
  • In 2020, The United States had the largest incident population of Antibody-Mediated Rejection in 7MM.
  • Among the EU5 countries, France had the highest Antibody-Mediated Rejection incident cases whereas Germany had the lowest incident cases in 2020.


Antibody-Mediated Rejection Market Insight

Antibody-Mediated Rejection market size in the 7MM was found to be USD 90.22 million in 2020.  


Antibody-Mediated Rejection Market Drivers


  • Emerging therapies
  • Development of personalised therapy
  • Targeting of novel pathways
  • Increased rate of organ donation
  • Development of gene therapy


Antibody-Mediated Rejection Market Barriers 


  • Challenges in designing clinical trials
  • High clinical burden
  • Need for evidence-based treatment guidelines


Antibody-Mediated Rejection Emerging Drugs


The emerging drugs of the Antibody-Mediated Rejection market are

  • Clazakizumab
  • Imlifidase
  • VIB4920
  • Inebilizumab-cdon
  • Daratumumab, and others


Antibody-Mediated Rejection Key Players 


The key players working in the Antibody-Mediated Rejection market are

  • CSL Behring
  • Hansa Biopharma
  • Viela Bio
  • Janssen Biotech, and others